<DOC>
	<DOCNO>NCT00724789</DOCNO>
	<brief_summary>The primary purpose study collect data incidence congenital malformation infant woman ongoing pregnancy control ovarian stimulation recombinant follicle stimulate hormone /ganirelix follow vitro fertilization ( IVF ) intra cytoplasmatic sperm injection ( ICSI ) , compare incidence group woman use long protocol gonadotropin release hormone agonist historical control .</brief_summary>
	<brief_title>Monitor Incidence Congenital Malformations Infants Women Who Have Been Treated With Ganirelix ( Orgalutran® ) ( Study 38644 ) ( P05966 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Puregon® ( recFSH ) /Orgalutran® group : Women pregnancy &gt; = 16 week Puregon® /Orgalutran® treatment IVF ICSI ET fresh embryo . Treatment define least one injection Orgalutran® . Women 18 39 year age ( inclusive ) day hCG . Women able willing sign inform consent . Controls Infants ( gestational age &gt; =16 week ) woman pregnant COH use GnRH agonist long protocol IVF ICSI ET fresh embryo . Infants woman 18 39 year age ( inclusive ) day hCG . The recent 1000 infant deliver prior January 1 , 2001 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Neonatal outcome</keyword>
	<keyword>Congenital malformation</keyword>
	<keyword>In-Vitro fertilization</keyword>
	<keyword>Controlled ovarian stimulation</keyword>
	<keyword>Follow-up</keyword>
</DOC>